Login Register
English
0

Cart

$ 0
OR
Catalog no Product name Protocol name IF Magazine title
A23310 Dylight 549, Goat Anti-Mouse IgG CDCA3 Predicts Poor Prognosis and Affects CD8+ T Cell Infiltration in Renal Cell Carcinoma(A23310-23) 23 Journal of Hematology & Oncology
A25022 IPKine™ HRP, Mouse Anti-Rabbit IgG LCS CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis.(A25022-12.8) 12.8 Journal of Experimental & Clinical Cancer Research 
KTB1100 CheKine™ Micro Lactate Assay Kit CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis.(KTB1100-12.8) 12.8 Journal of Experimental & Clinical Cancer Research 
KTB1121 CheKine™ Micro Pyruvate Acid (PA) Assay Kit CDCA3-MYC positive feedback loop promotes bladder cancer progression via ENO1-mediated glycolysis.(KTB1121-12.8) 12.8 Journal of Experimental & Clinical Cancer Research
A23320 Dylight 549, Goat Anti-Rabbit IgG Cdh23 Gene Mutation–Induced Vestibular Dysfunction in Mice: Abnormal Stereocilia Bundle and Otolith Development and Activation of p53/FoxO Signaling Pathway.(A23320-2.7) 2.7 Journal of Molecular Neuroscience 
BMU107 CDK1 depletion suppresses glioma malignancy through cell cycle pathway regulation: Mechanistic insights from functional and molecular profiling(BMU107-2.2) 2.2 Frontiers in Pharmacology
ABT2020 Anti-GFP Tag Mouse Monoclonal Antibody (3D3) CDK1 mediates the metabolic regulation of DNA double-strand break repair in metaphase II oocytes.(ABT2020-4.5) 4.5 BMC biology 
A23220 Dylight 488, Goat Anti-Rabbit IgG CDK11p110 plays a critical role in the tumorigenicity of esophageal squamous cell carcinoma cells and is a potential drug target(A23220-2) 2 Cell Cycle
A23210 DyLight 488, Goat Anti-Mouse IgG CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy(A23210-15.7) 15.7 Oncogene
A23420 Dylight 594, Goat Anti-Rabbit IgG CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy(A23420-15.7) 15.7 Nat Commun